Novo Nordisk's Defensive Playbook: Lawsuits, Loyalty Shifts, and the Oral GLP-1 Squeeze
Published on 08/15/2026 at 18:07 | Redaktion boerse-global.de
The Danish pharmaceutical heavyweight is waging a quiet war on multiple fronts — and the market is watching closely. Novo Nordisk's shares closed Friday at EUR 39.40, down 2.6 percent on the day, extending a slide that now shows an 11 percent decline over the past 30 days and an identical drop since the start of the year. The stock sits 4.7 percent below its 50-day moving average of EUR 41.34, a technical picture that reflects the deepening unease surrounding the company's competitive position.
Legal Offensive Targets Rivals and Compounding Pharmacies
At the center of the company's defensive strategy is a freshly filed lawsuit in a US district court accusing Eli Lilly of misleading advertising and false marketing claims related to its obesity treatments. Novo contends that Lilly is seeking an unfair edge in the fiercely contested GLP-1 market. The legal salvo comes just days after Lilly announced on August 7 its official timeline for FDA submission of its next-generation obesity drug — a move that intensifies pressure on Novo's Wegovy franchise.
The litigation is not confined to American soil. On August 6, a Dutch district court in The Hague granted Novo a preliminary injunction against Ceban Ziekenhuisfarmacie, a Netherlands-based pharmacy, barring it from manufacturing and selling Semanova, a semaglutide-containing nasal spray, on patent infringement grounds. An autumn ruling from the Dutch Health and Youth Inspectorate is also anticipated regarding alleged violations of pharmaceutical law by compounding pharmacies.
These legal maneuvers underscore how critical market exclusivity for semaglutide has become, particularly as cheaper copycat products and compounded variants chip away at the company's pricing power.
The Foundayo Factor Reshapes the Oral GLP-1 Race
The more immediate competitive threat, however, comes from across the Atlantic. On August 10, Eli Lilly's Foundayo (orforglipron) received approval in the UK — the second oral GLP-1 weight-loss pill to enter the European market, arriving just two months after Novo launched its own Wegovy pill.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The product differentiation is stark: Foundayo requires no food restrictions, while Novo's oral offering demands administration on an empty stomach with a 30-minute wait before eating. What might seem like a minor inconvenience is, in practice, a significant commercial differentiator. Compliance is the deciding factor for oral GLP-1 success, and a more forgiving dosing regimen could sway both physicians and patients toward Lilly's product.
The early sales figures for Novo's Wegovy pill do little to dispel concerns. Second-quarter 2026 revenue of DKK 3.22 billion came in slightly below analyst expectations of DKK 3.27 billion, despite more than five million prescriptions since its January launch. Volume is clearly there; monetization is lagging — a pattern that could worsen as competitive pressure mounts.
Analyst Divergence Reflects Genuine Uncertainty
The sell-side is split on what comes next. Berenberg downgraded the stock from Buy to Hold on August 12, signaling growing skepticism about near-term prospects. On the same day, BMO Capital Markets raised its price target to USD 47 from USD 45 and lifted 2026 earnings estimates following the quarterly results — while simultaneously flagging pricing pressure and pointing to the September Capital Markets Day as the moment for greater clarity.
Rather than a contradiction, this divergence reads as authentic uncertainty. Even institutions maintaining faith in the company's operational fundamentals are reluctant to commit fully before the September event.
Strategic Pivots: Agency Shifts and AI Ambitions
Beyond the courtroom battles, Novo is restructuring its commercial operations. The company has appointed Omnicom as its lead agency for the US media account, ending a four-year partnership with WPP. The transition is designed to scale consumer engagement for Ozempic and Wegovy more effectively.
In parallel, Novo announced a strategic collaboration with Amazon Web Services to establish a co-innovation hub in London focused on AI-driven drug discovery. The center aims to compress the timeline from drug target identification to first human application. CEO Mike Doustdar recently emphasized that the company intends to satisfy US demand for the Wegovy pill before expanding into additional international markets — a cautionary approach born of past supply constraints.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The Dutch court ruling against unauthorized semaglutide nasal sprays, announced the same day as the AWS partnership, reinforces the message that Novo will defend its intellectual property vigorously. Both developments are solid strategic moves, yet neither offers immediate catalysts for the share price.
Technical Indicators Paint a Cautious Picture
The chart tells its own story. With an RSI of 40.6, the stock is not oversold but is clearly trading in weak territory. It sits 2.2 percent below its 200-day average, and the annualized volatility of 40 percent reflects a market pricing in considerable nervousness. The interim dividend of DKK 3.75 per share, scheduled for August 14, offers income-oriented investors some stability but does little to address the structural question: Can Novo defend its oral GLP-1 leadership when Lilly arrives with a more convenient alternative?
The coming weeks leading up to the Capital Markets Day in September are likely to be dominated by this uncertainty. The legal actions, the agency overhaul, and the AI partnerships all speak to a management team fighting hard on multiple fronts. But with the competitive landscape shifting beneath it, the market is withholding judgment — and the share price is reflecting that wait-and-see posture with every session.
Ad
Novo Nordisk Stock: New Analysis - 15 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
